Neuropathic Pain Scale (NPS)

Size: px
Start display at page:

Download "Neuropathic Pain Scale (NPS)"

Transcription

1 Neuropathic Pain Scale (NPS) Questionnaire Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by Business & Decision Life Sciences and the CDISC Questionnaire Sub-team Notes to Readers This supplement is intended to be used with other CDISC User Guides for specific Therapeutic/Disease Areas and follows the CDISC Study Data Tabulation Model Implementation Guide for Human Clinical trials. Revision History Date Version Summary of Changes Neuropathic Pain Scale (NPS) Draft Neuropathic Pain Scale (NPS) 2014 Clinical Data Interchange Standards Consortium, Inc. All rights reserved

2 1 Introduction This document describes the CDISC implementation of the Neuropathic Pain Scale (NPS) questionnaire, a standard questionnaire that is typically used in clinical trials to assess distinct pain qualities associated with neuropathic pain. The NPS questionnaire preceded the CDISC CDASH CRF standards and based on its public domain status, cannot be modified to CDASH standards. The representation of data collected for this questionnaire is based on the Study Data Tabulation Model Implementation Guide (SDTMIG) QS domain model, which can be found at the CDISC website at: ( These specific implementation details for this questionnaire are meant to be used in conjunction with the SDTMIG. All questionnaire documentation can be found on the CDISC web site at: ( The CDISC Intellectual Property Policy can be found on the CDISC web site at: ( 1.1 Representations and Warranties, Limitations of Liability, and Disclaimers This document is a supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials and is covered under Appendix F of that document, which describes representations, warranties, limitations of liability, and disclaimers. Please see Appendix F of the SDTMIG for a complete version of this material. 2 Copyright Status This instrument is copyright approved. CDISC has included the Neuropathic Pain Scale (NPS) as part of CDISC Data Standards. Hence, CDISC developed QSTESTCD and QSTEST for each question based on the actual question text on the questionnaire. There may be many versions of this questionnaire in the public domain or copyright questionnaire. CDISC has chosen to use this version as the data standard. The CDISC documentation of this instrument consists of: (1) controlled terminology, (2) standard database structure with examples, and (3) case report forms annotated with the CDISC SDTMIG submission values. Note: CDISC controlled terminology is maintained by NCI EVS. The most recent version should be accessed through the CDISC website. ( CDISC has developed this documentation at no cost to users of the instrument. CDISC acknowledges Brad Galer and Mark Jensen: Development and preliminary validation of a pain measure specific to neuropathic pain: The Neuropathic Pain Scale. NEUROLOGY 1997; 48: ) for including the NPS in the CDISC data standards Clinical Data Interchange Standards Consortium, Inc. All rights reserved

3 3 The QS Domain Model 3.1 Assumptions for Questionnaire Domain Model All assumptions and business rules described in the SDTMIG QS domain are applicable to this supplement. Additional assumptions specific to the Neuropathic Pain Scale are listed below. Neuropathic Pain Scale (NPS): NPS is a self-report questionnaire consisting of 10 items. Subjects rate 9 items on a numeric rating scale of 0-10, and describe the pain for one item. 1. Visual analog or numeric rating scales used within a questionnaire with a range of text and numeric values are indicated in the SUPPQS domain with: QNAM=RNGTXTLO QNAM=RNGVALLO QNAM=RNGTXTHI QNAM=RNGVALHI By storing this information in SUPPQS, it is available for interpretation purposes. The SDS QS Team is researching alternative methods to handle this data in the future, but until a new method is identified, this will be the recommended approach. a. The low and high anchor text is stored in QSORRES with the numeric values of these anchors stored in QSSRTESC and QSSTRESN. All other numeric values are stored in QSORRES, QSSTRESC and QSSTRESN. 2. The questionnaire evaluator is stored in QSEVAL. For NPS, the evaluator is defined as the STUDY SUBJECT. 3. Terminology: a. QSCAT, QSTESTCD and QSTEST are approved CDISC controlled terminology. b. A full list of value sets for qualifier and result fields is provided in Section 4: SDTM Mapping Strategy Clinical Data Interchange Standards Consortium, Inc. All rights reserved

4 3.2 Example for Neuropathic Pain Scale (NPS) QS Domain Model The NPS example below shows the terminology used to implement the questionnaire in the QS domain. This example shows the data for one subject collected at one visit for an NPS questionnaire. The example uses CDISC controlled terminology for QSTESTCD, QSTEST, and QSCAT. QSBLFL is NULL based on VISITNUM = 2. All original results for the NUMERICAL RATING SCALE 11-POINT are populated with the low and high anchor text and the scoring of 1 to 9 in QSORRES. This numerical result (scoring of 0 to 10) is then populated in QSSTRESC and QSSTRESN. Rows 1-7: Row 8: Rows 9 and 10: Rows 11-13: Row 21: Row 22: Row 33: Row 34: Represents the questions 1-7 from the NPS form. Represents the question 8 from the NPS form. Only one result is supposed to be checked for this question. Any unchecked result is not represented in SDTM. In this example first result of question 8 is checked. As first result of question 8 is checked, QSTESTCD = NPS0108A and NPS0108B are filled with text. Represents the questions 9 and 10 from the NPS form In this example second result of question 8 is checked. As second result of question 8 is checked, QSTESTCD = NPS0108C is filled with text. In this example third result of question 8 is checked. As third result of question 8 is checked, QSTESTCD = NPS0108D is filled with text. qs.xpt Row STUDYID DOMAIN USUBJID QSSEQ QSTESTCD QSTEST QSCAT 1 STUDYX QS P NPS 0101 NPS01-Tell Us How Intense Your Pain Is NPS STUDYX QS P NPS 0102 NPS01-Tell Us How Sharp Your Pain Feels NPS Not sharp STUDYX QS P NPS 0103 NPS01-Tell Us How Hot Your Pain Feels NPS STUDYX QS P NPS 0104 NPS01-Tell Us How Dull Your Pain Feels NPS The most dull sensation imaginable STUDYX QS P NPS 0105 NPS01-Tell Us How Cold Your Pain Feels NPS STUDYX QS P NPS 0106 NPS01-Sensitiv Skin to Light Touch/Cloth NPS STUDYX QS P NPS 0107 NPS01-Tell Us How Itchy Your Pain Feels NPS STUDYX QS P NPS0108 NPS01-Describe Time Quality of Your Pain NPS I feel background pin all the time I feel background pin all the time 2014 Clinical Data Interchange Standards Consortium, Inc. All rights reserved Page 4

5 and occasional flare-ups (break through pain) some of the time. and occasional flare-ups (break through pain) some of the time. 9 STUDYX QS P NPS 0108A NPS01-Describe the Background Pain NPS Intense pain Intense pain 10 STUDYX QS P NPS 0108B NPS01-Describe the Flare-up Pain NPS Rather ok Rather ok 11 STUDYX QS P NPS 0109 NPS01-Tell How Unpleasant Your Pain Feel NPS STUDYX QS P NPS 0110A NPS01-How Intense is Your Deep Pain NPS 13 STUDYX QS P NPS 0110B NPS01-How Intense is Your Surface Pain NPS STUDYX QS P NPS 0101 NPS01-Tell Us How Intense Your Pain Is NPS No pain STUDYX QS P NPS 0102 NPS01-Tell Us How Sharp Your Pain Feels NPS P0002 The most hot sensation imaginable 16 STUDYX QS 3 NPS 0103 NPS01-Tell Us How Hot Your Pain Feels NPS ( on fire ) 17 STUDYX QS P NPS 0104 NPS01-Tell Us How Dull Your Pain Feels NPS 18 STUDYX QS P NPS 0105 NPS01-Tell Us How Cold Your Pain Feels NPS STUDYX QS P NPS 0106 NPS01-Sensitiv Skin to Light Touch/Cloth NPS STUDYX QS P NPS 0107 NPS01-Tell Us How Itchy Your Pain Feels NPS P0002 I feel a single type of pain all the I feel a single type of pain all the 21 STUDYX QS 8 NPS0108 NPS01-Describe Time Quality of Your Pain NPS time. time. 22 STUDYX QS P NPS 0108C NPS01-Describe Single Type Pain All Time NPS Limited pain Limited pain 23 STUDYX QS P NPS 0109 NPS01-Tell How Unpleasant Your Pain Feel NPS STUDYX QS P NPS 0110A NPS01-How Intense is Your Deep Pain NPS 25 STUDYX QS P NPS 0110B NPS01-How Intense is Your Surface Pain NPS STUDYX QS P NPS 0101 NPS01-Tell Us How Intense Your Pain Is NPS STUDYX QS P NPS 0102 NPS01-Tell Us How Sharp Your Pain Feels NPS STUDYX QS P NPS 0103 NPS01-Tell Us How Hot Your Pain Feels NPS STUDYX QS P NPS 0104 NPS01-Tell Us How Dull Your Pain Feels NPS 30 STUDYX QS P NPS 0105 NPS01-Tell Us How Cold Your Pain Feels NPS Not cold STUDYX QS P NPS 0106 NPS01-Sensitiv Skin to Light Touch/Cloth NPS STUDYX QS P NPS 0107 NPS01-Tell Us How Itchy Your Pain Feels NPS P0003 I feel a single type of pain I feel a single type of pain 33 STUDYX QS 8 NPS0108 NPS01-Describe Time Quality of Your Pain NPS sometimes. Other times, I am pain free. sometimes. Other times, I am pain free. 34 STUDYX QS P NPS 0108D NPS01-Describe the Occasional Pain NPS Moderate pain Moderate pain 35 STUDYX QS P NPS 0109 NPS01-Tell How Unpleasant Your Pain Feel NPS P0003 The most intense deep pain 36 STUDYX QS 11 NPS 0110A NPS01-How Intense is Your Deep Pain NPS sensation imaginable 37 STUDYX QS P NPS 0110B NPS01-How Intense is Your Surface Pain NPS Clinical Data Interchange Standards Consortium, Inc. All rights reserved Page 5

6 Row QSMETHOD QSBLFL QSEVAL VISITNUM QSDTC QSDY 1 (cont) NUMERICAL RATING SCALE 11-POINT STUDY SUBJECT (cont) NUMERICAL RATING SCALE 11-POINT STUDY SUBJECT (cont) NUMERICAL RATING SCALE 11-POINT STUDY SUBJECT (cont) NUMERICAL RATING SCALE 11-POINT STUDY SUBJECT (cont) NUMERICAL RATING SCALE 11-POINT STUDY SUBJECT (cont) NUMERICAL RATING SCALE 11-POINT STUDY SUBJECT (cont) NUMERICAL RATING SCALE 11-POINT STUDY SUBJECT (cont) STUDY SUBJECT (cont) STUDY SUBJECT (cont) STUDY SUBJECT (cont) NUMERICAL RATING SCALE 11-POINT STUDY SUBJECT (cont) NUMERICAL RATING SCALE 11-POINT STUDY SUBJECT (cont) NUMERICAL RATING SCALE 11-POINT STUDY SUBJECT (cont) NUMERICAL RATING SCALE 11-POINT STUDY SUBJECT (cont) NUMERICAL RATING SCALE 11-POINT STUDY SUBJECT (cont) NUMERICAL RATING SCALE 11-POINT STUDY SUBJECT (cont) NUMERICAL RATING SCALE 11-POINT STUDY SUBJECT (cont) NUMERICAL RATING SCALE 11-POINT STUDY SUBJECT (cont) NUMERICAL RATING SCALE 11-POINT STUDY SUBJECT (cont) NUMERICAL RATING SCALE 11-POINT STUDY SUBJECT (cont) STUDY SUBJECT (cont) STUDY SUBJECT (cont) NUMERICAL RATING SCALE 11-POINT STUDY SUBJECT (cont) NUMERICAL RATING SCALE 11-POINT STUDY SUBJECT (cont) NUMERICAL RATING SCALE 11-POINT STUDY SUBJECT (cont) NUMERICAL RATING SCALE 11-POINT STUDY SUBJECT (cont) NUMERICAL RATING SCALE 11-POINT STUDY SUBJECT (cont) NUMERICAL RATING SCALE 11-POINT STUDY SUBJECT (cont) NUMERICAL RATING SCALE 11-POINT STUDY SUBJECT (cont) NUMERICAL RATING SCALE 11-POINT STUDY SUBJECT (cont) NUMERICAL RATING SCALE 11-POINT STUDY SUBJECT (cont) NUMERICAL RATING SCALE 11-POINT STUDY SUBJECT (cont) STUDY SUBJECT (cont) STUDY SUBJECT (cont) NUMERICAL RATING SCALE 11-POINT STUDY SUBJECT (cont) NUMERICAL RATING SCALE 11-POINT STUDY SUBJECT (cont) NUMERICAL RATING SCALE 11-POINT STUDY SUBJECT Clinical Data Interchange Standards Consortium, Inc. All rights reserved Page 6

7 The ranges (both numeric and text) of the numeric 10-point scale need to be populated in SUPPQS as follows. The standard terminology for QNAM and QLABEL are listed below. This is the current approach for this type of data until a better metadata solution is determined. QEVAL is not populated, since this is objective data based on the NPS CRF. (Only subject P0001 is represented in this example) suppqs.xpt STUDYID RDOMAIN USUBJID IDVAR IDVARVAL QNAM QLABEL QVAL QORIG QEVAL STUDYX QS P0001 QSTESTCD NPS 0101 RNGTXTLO Range Text Lo No pain ASSIGNED STUDYX QS P0001 QSTESTCD NPS 0101 RNGTXTHI Range Text Hi The most intense pain sensation imaginable ASSIGNED STUDYX QS P0001 QSTESTCD NPS 0101 RNGVALLO Range Value Lo 0 ASSIGNED STUDYX QS P0001 QSTESTCD NPS 0101 RNGVALHI Range Value Hi 10 ASSIGNED STUDYX QS P0001 QSTESTCD NPS 0102 RNGTXTLO Range Text Lo Not sharp ASSIGNED STUDYX QS P0001 QSTESTCD NPS 0102 RNGTXTHI Range Text Hi The most sharp sensation imaginable ( like a knife ) ASSIGNED STUDYX QS P0001 QSTESTCD NPS 0102 RNGVALLO Range Value Lo 0 ASSIGNED STUDYX QS P0001 QSTESTCD NPS 0102 RNGVALHI Range Value Hi 10 ASSIGNED STUDYX QS P0001 QSTESTCD NPS 0103 RNGTXTLO Range Text Lo Not hot ASSIGNED STUDYX QS P0001 QSTESTCD NPS 0103 RNGTXTHI Range Text Hi The post hot sensation imaginable ( on fire ) ASSIGNED STUDYX QS P0001 QSTESTCD NPS 0103 RNGVALLO Range Value Lo 0 ASSIGNED STUDYX QS P0001 QSTESTCD NPS 0103 RNGVALHI Range Value Hi 10 ASSIGNED STUDYX QS P0001 QSTESTCD NPS 0104 RNGTXTLO Range Text Lo Not dull ASSIGNED STUDYX QS P0001 QSTESTCD NPS 0104 RNGTXTHI Range Text Hi The most dull sensation imaginable ASSIGNED STUDYX QS P0001 QSTESTCD NPS 0104 RNGVALLO Range Value Lo 0 ASSIGNED STUDYX QS P0001 QSTESTCD NPS 0104 RNGVALHI Range Value Hi 10 ASSIGNED STUDYX QS P0001 QSTESTCD NPS 0105 RNGTXTLO Range Text Lo Not cold ASSIGNED STUDYX QS P0001 QSTESTCD NPS 0105 RNGTXTHI Range Text Hi The most cold sensation imaginable ( Freezing ) ASSIGNED STUDYX QS P0001 QSTESTCD NPS 0105 RNGVALLO Range Value Lo 0 ASSIGNED STUDYX QS P0001 QSTESTCD NPS 0105 RNGVALHI Range Value Hi 10 ASSIGNED STUDYX QS P0001 QSTESTCD NPS 0106 RNGTXTLO Range Text Lo Not sensitive ASSIGNED STUDYX QS P0001 QSTESTCD NPS 0106 RNGTXTHI Range Text Hi The most sensitive sensation imaginable ( raw skin ) ASSIGNED STUDYX QS P0001 QSTESTCD NPS 0106 RNGVALLO Range Value Lo 0 ASSIGNED STUDYX QS P0001 QSTESTCD NPS 0106 RNGVALHI Range Value Hi 10 ASSIGNED STUDYX QS P0001 QSTESTCD NPS 0107 RNGTXTLO Range Text Lo Not itchy ASSIGNED STUDYX QS P0001 QSTESTCD NPS 0107 RNGTXTHI Range Text Hi The most itchy sensation imaginable ( like poison oak ) ASSIGNED STUDYX QS P0001 QSTESTCD NPS 0107 RNGVALLO Range Value Lo 0 ASSIGNED STUDYX QS P0001 QSTESTCD NPS 0107 RNGVALHI Range Value Hi 10 ASSIGNED STUDYX QS P0001 QSTESTCD NPS 0109 RNGTXTLO Range Text Lo Not unpleasant ASSIGNED STUDYX QS P0001 QSTESTCD NPS 0109 RNGTXTHI Range Text Hi The most unpleasant sensation imaginable ( intolerable )² ASSIGNED STUDYX QS P0001 QSTESTCD NPS 0109 RNGVALLO Range Value Lo 0 ASSIGNED STUDYX QS P0001 QSTESTCD NPS 0109 RNGVALHI Range Value Hi 10 ASSIGNED STUDYX QS P0001 QSTESTCD NPS 0110A RNGTXTLO Range Text Lo No deep pain ASSIGNED 2014 Clinical Data Interchange Standards Consortium, Inc. All rights reserved Page 7

8 STUDYID RDOMAIN USUBJID IDVAR IDVARVAL QNAM QLABEL QVAL QORIG QEVAL STUDYX QS P0001 QSTESTCD NPS 0110A RNGTXTHI Range Text Hi The most intense deep pain sensation imaginable ASSIGNED STUDYX QS P0001 QSTESTCD NPS 0110A RNGVALLO Range Value Lo 0 ASSIGNED STUDYX QS P0001 QSTESTCD NPS 0110A RNGVALHI Range Value Hi 10 ASSIGNED STUDYX QS P0001 QSTESTCD NPS 0110B RNGTXTLO Range Text Lo No surface pain ASSIGNED STUDYX QS P0001 QSTESTCD NPS 0110B RNGTXTHI Range Text Hi The most intense surface pain sensation imaginable ASSIGNED STUDYX QS P0001 QSTESTCD NPS 0110B RNGVALLO Range Value Lo 0 ASSIGNED STUDYX QS P0001 QSTESTCD NPS 0110B RNGVALHI Range Value Hi 10 ASSIGNED 2014 Clinical Data Interchange Standards Consortium, Inc. All rights reserved Page 8

9 4 SDTM Mapping Strategy NPS specific mapping strategy: This section is used for reference with the annotated CRF for further details on the CRF data capture and to understand the alignment of the questionnaire to the SDTM QS domain. It also provides guidance on how the result variables (QSORRES, QSSTRESC, and QSSTRESN) should be populated for the questionnaire. If a result variable is not included in the table for a questionnaire, it should not be populated. QSMETHOD NUMERICAL RATING SCALE 11-POINT Applicable to QSTESTCD NPS0101-NPS0107 and NPS0109-NPS0110B QSTESTCD = NPS0101, QSTEST= NPS01-Tell Us How Intense Your Pain Is No pain 0 0 The most intense pain sensation imaginable QSTESTCD = NPS0102, QSTEST= NPS01-Tell Us How Sharp Your Pain Feels Not sharp 0 0 The most sharp sensation imaginable ( like a knife ) QSTESTCD = NPS0103, QSTEST= NPS01-Tell Us How Hot Your Pain Feels Not hot 0 0 The most hot sensation imaginable ( on fire ) QSTESTCD = NPS0104, QSTEST= PS01-Tell Us How Dull Your Pain Feels Not dull 0 0 The most dull sensation imaginable Clinical Data Interchange Standards Consortium, Inc. All rights reserved Page 9

10 QSTESTCD = NPS0105, QSTEST= NPS01-Tell Us How Cold Your Pain Feels Not cold 0 0 The most cold sensation imaginable ( freezing ) QSTESTCD = NPS0106, QSTEST= NPS01-Sensitiv Skin to Light Touch/Cloth Not sensitive 0 0 The most sensitive sensation imaginable ( raw skin ) QSTESTCD = NPS0107, QSTEST= NPS01-Tell Us How Itchy Your Pain Feels Not itchy 0 0 The most itchy sensation imaginable ( like poison oak ) QSTESTCD = NPS0108, QSTEST= NPS01-Describe Time Quality of Your Pain QSORRES QSSTRESC I feel a background pain all of the time and occasional flare-ups (break-through pain) some of the time I feel a background pain all of the time and occasional flare-ups (break-through pain) some of the time I feel a single type of pain all the time I feel a single type of pain all the time I feel a single type of pain only sometimes. Other times, I am free I feel a single type of pain only sometimes. Other times, I am free QSTESTCD = NPS0109, QSTEST= NPS01-Tell How Unpleasant Your Pain Feel Not unpleasant 0 0 The most unpleasant sensation imaginable ( intolerable ) QSTESTCD = NPS0110A, QSTEST= NPS01-How Intense is Your Deep Pain No deep pain 0 0 The most intense deep pain sensation imaginable Clinical Data Interchange Standards Consortium, Inc. All rights reserved

11 QSTESTCD = NPS0110B, QSTEST= NPS01-How Intense is Your Surface Pain No surface pain 0 0 The most intense surface pain sensation imaginable SUPPQS.QVAL value standardization for data range text values QNAM QVAL Applicable to QSTESTCD RNGTXTLO No pain NPS0101 RNGTXTLO Not sharp NPS0102 RNGTXTLO Not hot NPS0103 RNGTXTLO Not dull NPS0104 RNGTXTLO Not cold NPS0105 RNGTXTLO Not sensitive NPS0106 RNGTXTLO Not itchy NPS0107 RNGTXTLO Not unpleasant NPS0109 RNGTXTLO No deep pain NPS0110A RNGTXTLO No surface pain NPS0110B RNGTXTHI The most intense pain sensation imaginable NPS0101 RNGTXTHI The most sharp sensation imaginable ( like a knife ) NPS0102 RNGTXTHI The most hot sensation imaginable ( on fire ) NPS0103 RNGTXTHI The most dull sensation imaginable NPS0104 RNGTXTHI The most cold sensation imaginable ( freezing ) NPS0105 RNGTXTHI The most sensitive sensation imaginable ( raw skin ) NPS0106 RNGTXTHI The most itchy sensation imaginable ( like poison oak ) NPS0107 RNGTXTHI The most unpleasant sensation imaginable ( intolerable ) NPS0109 RNGTXTHI The most intense deep pain sensation imaginable NPS0110A RNGTXTHI The most intense surface pain sensation imaginable NPS0110B 5 Supplemental Qualifier Name Codes The following table contains an additional standard name codes for use in the Supplemental Qualifiers for Questionnaires (SUPPQS) special-purpose dataset. QNAM QLABEL Applicable Domains RNGTXTLO Range Text Lo QS RNGTXTHI Range Text Hi QS RNGVALLO Range Value Lo QS RNGVALHI Range Value Hi QS End of Document 2014 Clinical Data Interchange Standards Consortium, Inc. All rights reserved

Short-Form McGill Pain Questionniare-2 (SHORT-FORM MPQ-2)

Short-Form McGill Pain Questionniare-2 (SHORT-FORM MPQ-2) Short-Form McGill Pain Questionniare-2 ( ) Questionnaire Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by CDISC and Analgesic Clinical Trial Translations,

More information

Pain Relief (PR) Notes to Readers

Pain Relief (PR) Notes to Readers Pain (PR) Questionnaire Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by CDISC and Analgesic Clinical Trial Translations, Innovations, Opportunities,

More information

Disability Assessment for Dementia (DAD)

Disability Assessment for Dementia (DAD) Disability Assessment for Dementia (DAD) Questionnaire Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by CAMD AD v1.1 Team and the CDISC Questionnaire

More information

Hospital Anxiety and Depression Scale (HADS)

Hospital Anxiety and Depression Scale (HADS) Hospital Anxiety and Depression Scale (HADS) Questionnaire Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by Business & Decision Life Sciences and

More information

Epworth Sleepiness Scale (ESS)

Epworth Sleepiness Scale (ESS) Epworth Sleepiness Scale (ESS) Questionnaire Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by CDISC Questionnaires Sub-team Notes to Readers This

More information

Modified Hachinski Ischemic Scale: NACC Version (MHIS-NACC) v.1.0

Modified Hachinski Ischemic Scale: NACC Version (MHIS-NACC) v.1.0 Modified Hachinski Ischemic Scale: NACC Version (MHIS-NACC) v.1.0 Questionnaire Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by CAMD AD v2.0 Team

More information

Brief Psychiatric Rating Scale-Anchored (BPRS-A)

Brief Psychiatric Rating Scale-Anchored (BPRS-A) Brief Psychiatric Rating Scale-Anchored (BPRS-A) Questionnaire Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by CDISC Questionnaire Sub-team Notes

More information

Columbia-Suicide Severity Rating Scale Baseline (C-SSRS BASELINE)

Columbia-Suicide Severity Rating Scale Baseline (C-SSRS BASELINE) Columbia-Suicide Severity Rating Scale Baseline ( ) Questionnaire Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by CDISC and Analgesic Clinical Trial

More information

Brief Psychiatric Rating Scale-Anchored (BPRS-A)

Brief Psychiatric Rating Scale-Anchored (BPRS-A) Brief Psychiatric Rating Scale-Anchored (BPRS-A) Questionnaire Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by CDISC Questionnaire Sub-team Notes

More information

Clinical Global Impression (CGI)

Clinical Global Impression (CGI) Clinical Global Impression (CGI) Questionnaire Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by CDISC and Analgesic Clinical Trial Translations,

More information

Barnes Akathisia Rating Scale (BARS)

Barnes Akathisia Rating Scale (BARS) Barnes Akathisia Rating Scale () Questionnaire Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by CDISC Questionnaire Sub-team Notes to Readers This

More information

Michigan Neuropathy Screening Instrument (MNSI)

Michigan Neuropathy Screening Instrument (MNSI) Michigan Neuropathy Screening Instrument () Questionnaire Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by CDISC and Analgesic Clinical Trial Translations,

More information

Columbia-Suicide Severity Rating Scale Baseline (C-SSRS BASELINE)

Columbia-Suicide Severity Rating Scale Baseline (C-SSRS BASELINE) Columbia-Suicide Severity Rating Scale Baseline ( ) Questionnaire Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by CDISC and Analgesic Clinical Trial

More information

Columbia-Suicide Severity Rating Scale Baseline (C-SSRS BASELINE)

Columbia-Suicide Severity Rating Scale Baseline (C-SSRS BASELINE) Columbia-Suicide Severity Rating Scale Baseline ( ) Questionnaire Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by CDISC and Analgesic Clinical Trial

More information

Timed Up and Go (TUG)

Timed Up and Go (TUG) Timed Up and Go (TUG) Functional Test Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by Multiple Sclerosis Outcomes Assessment Consortium and the

More information

Hamilton Depression Rating Scale 17-Item (HAMD 17)

Hamilton Depression Rating Scale 17-Item (HAMD 17) Hamilton Depression Rating Scale -Item ( ) Questionnaire Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by CDISC and Analgesic Clinical Trial Translations,

More information

Unified Parkinson's Disease Rating Scale UPDRS

Unified Parkinson's Disease Rating Scale UPDRS Unified Parkinson's Disease Rating Scale Questionnaire Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by CDISC and National Institute of Neurological

More information

Unified Parkinson's Disease Rating Scale UPDRS

Unified Parkinson's Disease Rating Scale UPDRS Unified Parkinson's Disease Rating Scale Questionnaire Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by CDISC and National Institute of Neurological

More information

Alzheimer s Disease-specific Therapeutic Area Supplement to the Study Data Tabulation Model User Guide

Alzheimer s Disease-specific Therapeutic Area Supplement to the Study Data Tabulation Model User Guide CDISC Alzheimer s disease SDTM User Guide (Version 1.0) Alzheimer s Disease-specific Therapeutic Area Supplement to the Study Data Tabulation Model User Guide Prepared by the Coalition Against Major Diseases

More information

PharmaSUG Paper DS04

PharmaSUG Paper DS04 PharmaSUG2014 - Paper DS04 Considerations in the Submission of Exposure Data in SDTM-Based Datasets Fred Wood, Accenture Life Sciences, Wayne, PA Jerry Salyers, Accenture Life Sciences, Wayne, PA Richard

More information

CDISC BrCa TAUG & Oncology Information Session

CDISC BrCa TAUG & Oncology Information Session 1 15 September 2016 CDISC BrCa TAUG & Oncology Information Session Barrie Nelson @ DCDISC 2 24 February 2016 10:00-11:30am CST CDISC Oncology Information Session Rhonda Facile, Ann White, John Owen, Diane

More information

Let s Create Standard Value Level Metadata

Let s Create Standard Value Level Metadata PRA Health Sciences PhUSE US Connect 2019 Paper DS12 February 27, 2019 David Fielding Value Level Metadata Value Level Metadata is an important part of the Define-XML that allows us to explain our study

More information

Therapeutic Area User Guide Cardiovascular V1.0 Public Review Webinar April 3, 2014

Therapeutic Area User Guide Cardiovascular V1.0 Public Review Webinar April 3, 2014 Therapeutic Area User Guide Cardiovascular V1.0 Public Review Webinar April 3, 2014 1 Therapeutic Area User Guide CV V1.0 Public Review Webinar April 3, 2014 James Tcheng, MD, FACC, DCRI Steve Kopko, CDISC,

More information

PharmaSUG Paper DS12

PharmaSUG Paper DS12 PharmaSUG 2017 - Paper DS12 Considerations and Conventions in the Submission of the SDTM Tumor and Response Domains Jerry Salyers, Accenture Accelerated R&D Services, Berwyn, PA Fred Wood, Accenture Accelerated

More information

SDTMIG v3.3 Batch 2 Upcoming Public Review. Presented by Fred Wood

SDTMIG v3.3 Batch 2 Upcoming Public Review. Presented by Fred Wood 1 SDTMIG v3.3 Batch 2 Upcoming Public Review Presented by Fred Wood 2 SDTMIG v3.3 Batch 2? What This package constitutes Batch 2 for the planned SDTMIG v3.3. It is planned to be available for a public

More information

Intervention ML: Mapping of Meal data. Rahul Loharkar, inventiv Health Clinical, Pune, India Sandeep Sawant, inventiv Health Clinical, Mumbai, India

Intervention ML: Mapping of Meal data. Rahul Loharkar, inventiv Health Clinical, Pune, India Sandeep Sawant, inventiv Health Clinical, Mumbai, India Paper DS06 Intervention ML: Mapping of Meal data. Rahul Loharkar, inventiv Health Clinical, Pune, India Sandeep Sawant, inventiv Health Clinical, Mumbai, India ABSTRACT The focus of most bioavailability/bioequivalence

More information

Jerry Salyers, Accenture Accelerated R&D Services Fred Wood, Accenture Accelerated R&D Services. PhUSE 2017 Edinburgh, Scotland Paper #DS05

Jerry Salyers, Accenture Accelerated R&D Services Fred Wood, Accenture Accelerated R&D Services. PhUSE 2017 Edinburgh, Scotland Paper #DS05 Jerry Salyers, Accenture Accelerated R&D Services Fred Wood, Accenture Accelerated R&D Services PhUSE 2017 Paper #DS05 } Review of Tumor domains and representative CRFs Ø TU (Tumor Identification) Ø TR

More information

Project Charter. Template v2 June 3, February 25, Name of Project: Prostate Cancer (PrCa) Therapeutic Area Data Standards

Project Charter. Template v2 June 3, February 25, Name of Project: Prostate Cancer (PrCa) Therapeutic Area Data Standards Project Charter Template v2 June 3, 2015 Name of Project: Prostate Cancer (PrCa) Therapeutic Area Data Standards February 25, 2016 Project Manager: John Owen 1. Scope of Prostate Cancer Therapeutic Area

More information

Examples: Tables. Descriptive stats with ANOVA, ANCOVA, and t test p values Frequency and percent Correlation coefficients

Examples: Tables. Descriptive stats with ANOVA, ANCOVA, and t test p values Frequency and percent Correlation coefficients Examples: Tables Descriptive stats with ANOVA, ANCOVA, and t test p values Frequency and percent Correlation coefficients Descriptive Statistics Table 1. Body Mass Index using Last Observation Carried

More information

CFAST Asthma Project. Rhonda Facile. CDISC International Interchange Session 4B: Therapeutic Area Standards in Action November 6, 2013

CFAST Asthma Project. Rhonda Facile. CDISC International Interchange Session 4B: Therapeutic Area Standards in Action November 6, 2013 CFAST Asthma Project Rhonda Facile CDISC International Interchange Session 4B: Therapeutic Area Standards in Action November 6, 2013 1 Asthma Project CFAST Development Principles Asthma Background What

More information

Therapeutic Area Data Standards User Guide for Cardiovascular Studies Version 1.0 (Provisional) Prepared by the CFAST Cardiovascular Team

Therapeutic Area Data Standards User Guide for Cardiovascular Studies Version 1.0 (Provisional) Prepared by the CFAST Cardiovascular Team Therapeutic Area Data Standards User Guide for Cardiovascular Studies Version 1.0 (Provisional) Prepared by the CFAST Cardiovascular Team Notes to Readers This is the provisional version 1.0 of the Therapeutic

More information

The Standard for the Exchange of Nonclinical Data (SEND): History, Basics, and Comparisons with Clinical Data

The Standard for the Exchange of Nonclinical Data (SEND): History, Basics, and Comparisons with Clinical Data Life Sciences Accelerated R&D Services The Science of Getting Products to Patients Faster The Standard for the Exchange of Nonclinical Data (SEND): History, Basics, and Comparisons with Clinical Data Fred

More information

CDISC - Mapping New Pathways for Novartis. Darren Weston, Project Leader Pat Majcher, Senior Principal Programmer

CDISC - Mapping New Pathways for Novartis. Darren Weston, Project Leader Pat Majcher, Senior Principal Programmer CDISC - Mapping New Pathways for Novartis Darren Weston, Project Leader Pat Majcher, Senior Principal Programmer Shuhong hong Xie, Senior Statistical Programmer Agenda What was the submission request?

More information

How to manage changes to CDISC standards at Novo Nordisk. PhUSE EU Connect 2018 Sune Dandanell and Mikkel Traun

How to manage changes to CDISC standards at Novo Nordisk. PhUSE EU Connect 2018 Sune Dandanell and Mikkel Traun How to manage changes to CDISC standards at Novo Nordisk PhUSE EU Connect 2018 Sune Dandanell and Mikkel Traun How to manage changes to CDISC standards at Novo Nordisk 06-Nov-2018 2 How to manage changes

More information

Breast Cancer TAUG Overview and Implementation

Breast Cancer TAUG Overview and Implementation Breast Cancer TAUG Overview and Implementation Anita Umesh, Ph.D. Senior Scientist, Enterprise Informatics Illumina, Inc. Bay Area CDISC User Group 9 December 2015 2014 Illumina, Inc. All rights reserved.

More information

CDISC Public Webinar- Post Traumatic Stress Disorder Therapeutic Area User Guide

CDISC Public Webinar- Post Traumatic Stress Disorder Therapeutic Area User Guide CDISC Public Webinar- Post Traumatic Stress Disorder Therapeutic Area User Guide 26 September 2017 Allyson Gage Cohen Veterans Biosciences Amy Palmer CDISC Kathleen Mellars CDISC Dana Booth - CDISC 1 AGENDA

More information

Design and Construct Efficacy Analysis Datasets in Late Phase Oncology Studies

Design and Construct Efficacy Analysis Datasets in Late Phase Oncology Studies PharmaSUG China Design and Construct Efficacy Analysis s in Late Phase Oncology Studies Huadan Li, MSD R&D (China) Co., Ltd., Beijing, China Changhong Shi, MSD R&D (China) Co., Ltd., Beijing, China ABSTRACT

More information

How to - Trial Summary Parameter. CJUG SDTM Team : LISaS

How to - Trial Summary Parameter. CJUG SDTM Team : LISaS How to - Trial Summary Parameter CJUG SDTM Team : LISaS 2013-11-08 Preconditions for the Discussion CDISC Controlled Terminology: As of 2013-10-04 SDTM IG: v3.1.3 or v3.1.2 CDISC Protocol Representation

More information

7 th November % of patients had lidocaine plasters prescribed for the licensed indication of post herpatic neuralgia

7 th November % of patients had lidocaine plasters prescribed for the licensed indication of post herpatic neuralgia Directorate of Integrated Care Health and Social Care Board 12-22 Linenhall Street Belfast BT2 8BS Tel : 028 90553782 Fax : 028 90553622 Web Site: www.hscboard.hscni.net 7 th November 2013 Dear colleague

More information

ADaM Considerations and Content in the TA User Guides. Susan J Kenny, PhD Maximum Likelihood, Inc.

ADaM Considerations and Content in the TA User Guides. Susan J Kenny, PhD Maximum Likelihood, Inc. ADaM Considerations and Content in the TA User Guides Susan J Kenny, PhD Maximum Likelihood, Inc. Topics to Discuss Focus of ADaM content Overview of TAUGs with ADaM content Specific ADaM content in selected

More information

CDISC SHARE. CDISC Shared Health and Research Electronic Library Pilot Report. Date: 19 January 2010 Version: 1.0 CDISC, 2010

CDISC SHARE. CDISC Shared Health and Research Electronic Library Pilot Report. Date: 19 January 2010 Version: 1.0 CDISC, 2010 CDISC SHARE CDISC Shared Health and Research Electronic Library Pilot Report Date: 19 January 2010 Version: 1.0 CDISC, 2010 Page 1 of 28 Document History Issue Author Date Description 0.1 Pilot Team 9

More information

CDISC Controlled Terminology. Presented by Chris Gemma and Erin Muhlbradt, Ph.D.

CDISC Controlled Terminology. Presented by Chris Gemma and Erin Muhlbradt, Ph.D. CDISC Controlled Terminology Presented by Chris Gemma and Erin Muhlbradt, Ph.D. Panelists Erin Muhlbradt, Clincal/Biomedical Information Specialist, MSC Chris Gemma, Project Manager, CDISC 2 Question &

More information

ADaM Grouping: Groups, Categories, and Criteria. Which Way Should I Go?

ADaM Grouping: Groups, Categories, and Criteria. Which Way Should I Go? ABSTRACT PharmaSUG 2017 - Paper DS17 ADaM Grouping: Groups, Categories, and Criteria. Which Way Should I Go? Jack Shostak, Duke Clinical Research Institute ADaM has variables that allow you to cluster,

More information

Measure #355: Unplanned Reoperation within the 30 Day Postoperative Period National Quality Strategy Domain: Patient Safety

Measure #355: Unplanned Reoperation within the 30 Day Postoperative Period National Quality Strategy Domain: Patient Safety Measure #355: Unplanned Reoperation within the 30 Day Postoperative Period National Quality Strategy Domain: Patient Safety 2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Outcome DESCRIPTION:

More information

RESEARCH STUDY: RELATIONSHIP BETWEEN PAIN AND SLEEP IN SPINAL CORD INJURY PATIENTS Pain perception : McGill Pain Questionnaire

RESEARCH STUDY: RELATIONSHIP BETWEEN PAIN AND SLEEP IN SPINAL CORD INJURY PATIENTS Pain perception : McGill Pain Questionnaire RESEARCH STUDY: RELATIONSHIP BETWEEN PAIN AND SLEEP IN SPINAL CORD INJURY PATIENTS Pain perception : McGill Pain Questionnaire Participants Name: Date: Time: PRI: S A E M PRI (TOTAL) PPI (1-10) (11-15)

More information

Standards for Analyzable Submission Datasets for Directed Safety Analyses

Standards for Analyzable Submission Datasets for Directed Safety Analyses Standards for Analyzable Submission Datasets for Directed Safety Analyses Michael Nessly Director, Clinical Biostatistics Merck Research Labs CDISC Analysis Dataset Models Team (ADaM) nesslym@merck.com

More information

The Movement Disorder Society Version of the Unified Parkinson's Disease Rating Scale MDS-UPDRS

The Movement Disorder Society Version of the Unified Parkinson's Disease Rating Scale MDS-UPDRS The Movement Disorder ociety Version of the Unified Parkinson's Disease ating cale Questionnaire upplement to the tudy Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by CDIC

More information

Measure #412: Documentation of Signed Opioid Treatment Agreement National Quality Strategy Domain: Effective Clinical Care

Measure #412: Documentation of Signed Opioid Treatment Agreement National Quality Strategy Domain: Effective Clinical Care Measure #412: Documentation of Signed Opioid Treatment Agreement National Quality Strategy Domain: Effective Clinical Care 2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Process DESCRIPTION:

More information

Row same as start date 513) Examples for Treatments Major Issue Closed

Row same as start date 513) Examples for Treatments Major Issue Closed 1 Please add a dot in line 1087, behind "membrane" Appendix E Typo Updated as requested 2 Please suggest to add abbreviation "NAC" and its definition (see line 1142) Appendix C Minor Issue Appendix C updated

More information

CDISC CONTROLLED TERMINOLOGY. Presented by Chris Gemma and Erin Muhlbradt, Ph.D.

CDISC CONTROLLED TERMINOLOGY. Presented by Chris Gemma and Erin Muhlbradt, Ph.D. 1 CDISC CONTROLLED TERMINOLOGY Presented by Chris Gemma and Erin Muhlbradt, Ph.D. CDISC 2018 2 Question & Answer Panelist : Question OR Presentation : Question Examples: 1) What should be supported by

More information

Data Management and CDISC Formatting for Transdermal Patches Lois Lynn, Noven Pharmaceuticals, Inc., Jersey City, NJ

Data Management and CDISC Formatting for Transdermal Patches Lois Lynn, Noven Pharmaceuticals, Inc., Jersey City, NJ PharmaSUG 2018 - Paper MD-05 ABSTRACT Data Management and CDISC Formatting for Transdermal Patches Lois Lynn, Noven Pharmaceuticals, Inc., Jersey City, NJ Transdermal patch use is an alternative delivery

More information

Where Is the Link Broken Another Look at SDTM Oncology Tumor Packages

Where Is the Link Broken Another Look at SDTM Oncology Tumor Packages PharmaSUG 2017 Paper DS07 Where Is the Link Broken Another Look at SDTM Oncology Tumor Packages ABSTRACT Hong WANG, Boehringer Ingelheim, Ridgefield, CT Ke XIAO, Boehringer Ingelheim, Ridgefield, CT CDISC

More information

PharmaSUG 2018 Paper AD-02

PharmaSUG 2018 Paper AD-02 PharmaSUG 2018 Paper AD-02 Derivations of Response Status from SDTM Domains using RECIST 1.1 Christine Teng, Merck Research Laboratories, Merck & Co., Inc., Rahway, NJ USA Pang Lei, Merck Research Laboratories,

More information

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Outcome High Priority

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Outcome High Priority Quality ID #355: Unplanned Reoperation within the 30 Day Postoperative Period National Quality Strategy Domain: Patient Safety Meaningful Measure Area: Admissions and Readmissions to Hospitals 2019 COLLECTION

More information

Quality ID #168 (NQF 0115): Coronary Artery Bypass Graft (CABG): Surgical Re-Exploration National Quality Strategy Domain: Effective Clinical Care

Quality ID #168 (NQF 0115): Coronary Artery Bypass Graft (CABG): Surgical Re-Exploration National Quality Strategy Domain: Effective Clinical Care Quality ID #168 (NQF 0115): Coronary Artery Bypass Graft (CABG): Surgical Re-Exploration National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE

More information

Leveraging Standards for Effective Visualization of Early Efficacy in Clinical Trial Oncology Studies

Leveraging Standards for Effective Visualization of Early Efficacy in Clinical Trial Oncology Studies PharmaSUG 2018 - Paper DV-26 Leveraging Standards for Effective Visualization of Early Efficacy in Clinical Trial Oncology Studies Kelci Miclaus and Lili Li, JMP Life Sciences SAS Institute ABSTRACT Solid

More information

2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process Measure #109: Osteoarthritis (OA): Function and Pain Assessment National Quality Strategy Domain: Person and Caregiver-Centered Experience and Outcomes 2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY

More information

National Institute for Health and Clinical Excellence

National Institute for Health and Clinical Excellence National Institute for Health and Clinical Excellence NICE pilot quality standards for social care: Consultation on the draft quality standard for Dementia: Supporting people to live well with dementia

More information

Robin Feldman, MBA & Joy Esterlitz, MS NINDS CDE Team The Emmes Corporation Rockville, MD USA. Thursday, September 14, 2017

Robin Feldman, MBA & Joy Esterlitz, MS NINDS CDE Team The Emmes Corporation Rockville, MD USA. Thursday, September 14, 2017 The National Institute of Neurological Disorders and Stroke (NINDS) and American Academy of Cerebral Palsy and Developmental Medicine (AACPDM) Cerebral Palsy Common Data Elements (CDE) Recommendations

More information

Graph Display of Patient Profile Using SAS

Graph Display of Patient Profile Using SAS PharmaSUG 2018 - Paper DV-17 Graph Display of Patient Profile Using SAS Yanwei Han, Seqirus USA Inc., Cambridge, MA Hongyu Liu, Seqirus USA Inc., Cambridge, MA ABSTRACT We usually create patient profile

More information

Clinical Review Report (Sample)

Clinical Review Report (Sample) CADTH COMMON DRUG REVIEW Clinical Review Report (Sample) GENERIC DRUG NAME (BRAND NAME) (Manufacturer) Indication: Text Disclaimer: The information in this document is intended to help Canadian health

More information

Measure #286: Dementia: Counseling Regarding Safety Concerns National Quality Strategy Domain: Patient Safety

Measure #286: Dementia: Counseling Regarding Safety Concerns National Quality Strategy Domain: Patient Safety Measure #286: Dementia: Counseling Regarding Safety Concerns National Quality Strategy Domain: Patient Safety 2017 OPTIONS F INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Process DESCRIPTION: Percentage

More information

Study Endpoint Considerations: Final PRO Guidance and Beyond

Study Endpoint Considerations: Final PRO Guidance and Beyond Study Endpoint Considerations: Final PRO Guidance and Beyond Laurie Burke Associate Director for Study Endpoints and Labeling OND/CDER/FDA Presented at: FIRST ANNUAL PATIENT REPORTED OUTCOMES (PRO) CONSORTIUM

More information

2018 CMS Web Interface

2018 CMS Web Interface CMS Web Interface PREV-7 (NQF 0041): Preventive Care and Screening: Influenza Immunization Measure Steward: PCPI CMS Web Interface V2.1 Page 1 of 19 06/25/ Contents INTRODUCTION... 3 CMS WEB INTERFACE

More information

CDISC Public Webinar Standards Updates and Additions. 9 Mar 2015

CDISC Public Webinar Standards Updates and Additions. 9 Mar 2015 CDISC Public Webinar Standards Updates and Additions 9 Mar 2015 Agenda Dyslipidemia John Glover, TransCelerate BioPharma Inc Martin Benson, ICON Kristin Kelly, Accenture Vladimir Kryzhanovski, Eli Lilly

More information

What to Expect in SDTMIG v3.3 Fred Wood, Accenture Accelerated R&D Services, Berwyn, PA

What to Expect in SDTMIG v3.3 Fred Wood, Accenture Accelerated R&D Services, Berwyn, PA PharmaSUG2015 - Paper DS14 What to Expect in SDTMIG v3.3 Fred Wood, Accenture Accelerated R&D Services, Berwyn, PA ABSTRACT The next version of the SDTMIG (version 3.3) is expected in Q3 of this year.

More information

Dementia Friendly Communities Recognition Process. Karishma Chandaria Dementia Friendly Communities Programme Manager

Dementia Friendly Communities Recognition Process. Karishma Chandaria Dementia Friendly Communities Programme Manager Dementia Friendly Communities Recognition Process Karishma Chandaria Dementia Friendly Communities Programme Manager Living well with dementia Development of DFCs Progress in creating dementia friendly

More information

Grading Lab Toxicities using NCI- Common Terminology Criteria for Adverse Events (CTCAE)

Grading Lab Toxicities using NCI- Common Terminology Criteria for Adverse Events (CTCAE) Paper DH03 Grading Lab Toxicities using NCI- Common Terminology Criteria for Adverse Events (CTCAE) Srinivas Veeragoni, BHC Pharmaceuticals Inc., Whippany, USA Ankur Mathur, Bayer Inc., Toronto, Canada

More information

Quality ID #357: Surgical Site Infection (SSI) National Quality Strategy Domain: Effective Clinical Care

Quality ID #357: Surgical Site Infection (SSI) National Quality Strategy Domain: Effective Clinical Care Quality ID #357: Surgical Site Infection (SSI) National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Outcome DESCRIPTION: Percentage

More information

2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY

2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY Measure #222 (NQF 0427): Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Elbow, Wrist or Hand Impairments National Quality Strategy Domain: Communication and Care Coordination

More information

University of Groningen. The Pain Quality Assessment Scale for epidermolysis bullosa Schrader, Nicholas; Yuen, Wing Y; Jonkman, Marcel F.

University of Groningen. The Pain Quality Assessment Scale for epidermolysis bullosa Schrader, Nicholas; Yuen, Wing Y; Jonkman, Marcel F. University of Groningen The Pain Quality Assessment Scale for epidermolysis bullosa Schrader, Nicholas; Yuen, Wing Y; Jonkman, Marcel F. Published in: Acta dermato-venereologica DOI: 10.2340/00015555-2827

More information

Institute of Medicine Workshop: DIGITAL DATA PRIORITIES FOR CONTINUOUS LEARNING IN HEALTH AND HEALTH CARE

Institute of Medicine Workshop: DIGITAL DATA PRIORITIES FOR CONTINUOUS LEARNING IN HEALTH AND HEALTH CARE Institute of Medicine Workshop: DIGITAL DATA PRIORITIES FOR CONTINUOUS LEARNING IN HEALTH AND HEALTH CARE Data Quality in Clinical Research 23 March 2012 Rebecca D. Kush, PhD President and CEO, CDISC CDISC

More information

ISA 540, Auditing Accounting Estimates, Including Fair Value Accounting Estimates, and Related Disclosures Issues and Task Force Recommendations

ISA 540, Auditing Accounting Estimates, Including Fair Value Accounting Estimates, and Related Disclosures Issues and Task Force Recommendations Agenda Item 1-A ISA 540, Auditing Accounting Estimates, Including Fair Value Accounting Estimates, and Related Disclosures Issues and Task Force Recommendations Introduction 1. Since the September 2016

More information

2019 CMS Web Interface

2019 CMS Web Interface CMS Web Interface PREV-5 (NQF 2372): Breast Cancer Screening Measure Steward: NCQA CMS Web Interface V3.0 Page 1 of 18 xx/xx/2018 Contents INTRODUCTION... 3 CMS WEB INTERFACE SAMPLING INFORMATION... 4

More information

IAASB Main Agenda (March 2005) Page Agenda Item. DRAFT EXPLANATORY MEMORANDUM ISA 701 and ISA 702 Exposure Drafts February 2005

IAASB Main Agenda (March 2005) Page Agenda Item. DRAFT EXPLANATORY MEMORANDUM ISA 701 and ISA 702 Exposure Drafts February 2005 IAASB Main Agenda (March 2005) Page 2005 579 Agenda Item 13-F DRAFT EXPLANATORY MEMORANDUM ISA 701 and ISA 702 Exposure Drafts February 2005 Introduction This memorandum provides some background to, and

More information

2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process Measure #143 (NQF 0384): Oncology: Medical and Radiation Pain Intensity Quantified National Quality Strategy Domain: Person and Caregiver-Centered Experience and Outcomes 2017 OPTIONS FOR INDIVIDUAL MEASURES:

More information

Program Overview March 2014

Program Overview March 2014 Program Overview March 2014 Approved Therapeutic Area Standards Projects Therapeutic Area Coordinating Organization(s) Project Manager Proposal Approval Date Stage 0 Stage 1 Stage 2 Stage 3a Stage 3b Stage

More information

DENOMINATOR: All patient visits for patients aged 21 years and older with a diagnosis of OA

DENOMINATOR: All patient visits for patients aged 21 years and older with a diagnosis of OA Quality ID #109: Osteoarthritis (OA): Function and Pain Assessment National Quality Strategy Domain: Person and Caregiver-Centered Experience and Outcomes 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY

More information

Measure Reporting via Registry: CPT only copyright 2015 American Medical Association. All rights reserved. 11/17/2015 Page 1 of 9

Measure Reporting via Registry: CPT only copyright 2015 American Medical Association. All rights reserved. 11/17/2015 Page 1 of 9 Measure #223 (NQF 0428): Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Neck, Cranium, Mandible, Thoracic Spine, Ribs, or Other General Orthopedic Impairments National

More information

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Efficiency

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Efficiency Quality ID #322: Cardiac Stress Imaging t Meeting Appropriate Use Criteria: Preoperative Evaluation in Low-Risk Surgery Patients National Quality Strategy Domain: Efficiency and Cost Reduction 2018 OPTIONS

More information

Measure #412: Documentation of Signed Opioid Treatment Agreement National Quality Strategy Domain: Effective Clinical Care

Measure #412: Documentation of Signed Opioid Treatment Agreement National Quality Strategy Domain: Effective Clinical Care Measure #412: Documentation of Signed Opioid Treatment Agreement National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY DESCRIPTION: All patients

More information

DENOMINATOR: All patients aged 18 years and older with a diagnosis of coronary artery disease seen within a 12 month period

DENOMINATOR: All patients aged 18 years and older with a diagnosis of coronary artery disease seen within a 12 month period Quality ID #6 (NQF 0067): Coronary Artery Disease (CAD): Antiplatelet Therapy National Quality Strategy Domain: Effective Clinical Care Meaningful Measure Area: Management of Chronic Conditions 2019 COLLECTION

More information

2018 CMS Web Interface

2018 CMS Web Interface CMS Web Interface PREV-7 (NQF 0041): Preventive Care and Screening: Influenza Immunization Measure Steward: PCPI CMS Web Interface V2.0 Page 1 of 19 11/13/2017 Contents INTRODUCTION... 3 CMS WEB INTERFACE

More information

Disclaimer. The following report contains a description of the request, request specifications, and results from the modular program run(s).

Disclaimer. The following report contains a description of the request, request specifications, and results from the modular program run(s). Disclaimer The following report(s) provides findings from an FDA initiated query using its Mini Sentinel pilot. While Mini Sentinel queries may be undertaken to assess potential medical product safety

More information

DENOMINATOR: All patients 18 and older prescribed opiates for longer than six weeks duration

DENOMINATOR: All patients 18 and older prescribed opiates for longer than six weeks duration Quality ID #412: Documentation of Signed Opioid Treatment Agreement National Quality Strategy Domain: Effective Clinical Care Meaningful Measure Area: Prevention and Treatment of Opioid and Substance Use

More information

Quality ID #178: Rheumatoid Arthritis (RA): Functional Status Assessment National Quality Strategy Domain: Effective Clinical Care

Quality ID #178: Rheumatoid Arthritis (RA): Functional Status Assessment National Quality Strategy Domain: Effective Clinical Care Quality ID #178: Rheumatoid Arthritis (RA): Functional Status Assessment National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Process

More information

Critical Path Institute Coalition Against Major Diseases (CAMD) Alzheimer s Clinical Trial Database

Critical Path Institute Coalition Against Major Diseases (CAMD) Alzheimer s Clinical Trial Database Critical Path Institute Coalition Against Major Diseases (CAMD) Alzheimer s Clinical Trial Database Dr. Carolyn Compton, M.D., Ph.D. Chief Executive Officer Critical Path Institute 1 What We Do DEVELOP

More information

2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY

2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY Measure #322: Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Preoperative Evaluation in Low Risk Surgery Patients National Quality Strategy Domain: Efficiency and Cost Reduction 2016 PQRS

More information

CDISC Public Webinar- Huntington's Disease Therapeutic Area User Guide

CDISC Public Webinar- Huntington's Disease Therapeutic Area User Guide CDISC Public Webinar- Huntington's Disease Therapeutic Area User Guide 12 September 2017 Jon Neville CDISC Daniel Olson- Critical Path Institute (C-Path) 1 AGENDA Project Background Introduction to Huntington's

More information

Copyright 2017 BioStar Nutrition Pte Ltd. All rights reserved. Published by Adam Glass.

Copyright 2017 BioStar Nutrition Pte Ltd. All rights reserved. Published by Adam Glass. CardioClear7.com 1 Copyright 2017 BioStar Nutrition Pte Ltd All rights reserved Published by Adam Glass. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any

More information

DENOMINATOR: All patients aged 18 years and older with a diagnosis of chronic hepatitis C cirrhosis

DENOMINATOR: All patients aged 18 years and older with a diagnosis of chronic hepatitis C cirrhosis Quality ID #401: Hepatitis C: Screening for Hepatocellular Carcinoma (HCC) in Patients with Cirrhosis National Quality Strategy Domain: Effective Clinical Care Meaningful Measure Area: Preventive Care

More information

SDTM, Implementation Guide, and User Guide Updates

SDTM, Implementation Guide, and User Guide Updates Accenture Life Sciences Rethink Reshape Restructure for better health outcomes. Octagon is Now Part of Accenture SDTM, Implementation Guide, and User Guide Updates Fred Wood July 2013 Agenda Model, IG,

More information

Measure #110 (NQF 0041): Preventive Care and Screening: Influenza Immunization National Quality Strategy Domain: Community/Population Health

Measure #110 (NQF 0041): Preventive Care and Screening: Influenza Immunization National Quality Strategy Domain: Community/Population Health Measure #110 (NQF 0041): Preventive Care and Screening: Influenza Immunization National Quality Strategy Domain: Community/Population Health 2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE

More information

*NOTE: When submitting CPT code and 99239, it is recommended the measure be submitted each time the code is submitted for hospital discharge.

*NOTE: When submitting CPT code and 99239, it is recommended the measure be submitted each time the code is submitted for hospital discharge. Quality ID #5 (NQF 0081): Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD) National Quality

More information

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process-High Priority

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process-High Priority Quality ID #463: Prevention of Post-Operative Vomiting (POV) Combination Therapy (Pediatrics) National Quality Strategy Domain: Patient Safety Meaningful Measure Area: Preventive Care 2019 COLLECTION TYPE:

More information

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process Quality ID #177: Rheumatoid Arthritis (RA): Periodic Assessment of Disease Activity National Quality Strategy Domain: Effective Clinical Care Measure Meaningful Measure Area: Management of Chronic Conditions

More information

Measure #389: Cataract Surgery: Difference Between Planned and Final Refraction - National Quality Strategy Domain: Effective Clinical Care

Measure #389: Cataract Surgery: Difference Between Planned and Final Refraction - National Quality Strategy Domain: Effective Clinical Care Measure #389: Cataract Surgery: Difference Between Planned and Final Refraction - National Quality Strategy Domain: Effective Clinical Care 2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE:

More information

ADaM Tips for Exposure Summary

ADaM Tips for Exposure Summary ABSTRACT PharmaSUG China 2016 Paper 84 ADaM Tips for Exposure Summary Kriss Harris, SAS Specialists Limited, Hertfordshire, United Kingdom Have you ever created the Analysis Dataset for the Exposure Summary

More information

Authors and Co-Authors,

Authors and Co-Authors, Neurology Journals Authorship Agreement Authors and Co-Authors, To make authorship and sponsorship transparent to all readers, Neurology has changed its policy to include as Authors those who have made

More information

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Efficiency

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Efficiency Quality ID #323: Cardiac Stress Imaging t Meeting Appropriate Use Criteria: Routine Testing After Percutaneous Coronary Intervention (PCI) National Quality Strategy Domain: Efficiency and Cost Reduction

More information